Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • En
  • Sv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance®
    • Oncoral
  • Partnering
  • Investors
    • Press releases
    • Financial reports
    • Presentations & articles
    • Events
    • Share information
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
  • Contact
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
Regulatory
2025-05-16 | Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission
PDF
Report
Presentation
Webcast
Regulatory
2025-02-07 | Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study
PDF
Report
Presentation
Webcast
Regulatory
2024-11-07 | Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025
PDF
Report
Presentation
Webcast
Regulatory
2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study
PDF
Report
Presentation
Webcast
Regulatory
2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study
PDF
Report
Presentation
Webcast
Regulatory
2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May
PDF
Report
Presentation
Webcast
Regulatory
2023-11-08 | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan
PDF
Report
Presentation
Webcast
Regulatory
2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE
PDF
Report
Presentation
Webcast
Regulatory
2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed
PDF
Report
Presentation
Webcast
Regulatory
2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023.
PDF
Report
Presentation
Webcast
Regulatory
2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission
PDF
Report
Presentation
Webcast
Regulatory
2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study
PDF
Report
Presentation
Webcast
Regulatory
2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals
PDF
Report
Presentation
Webcast
Regulatory
2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent
PDF
Report
Presentation
Webcast
Regulatory
2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration
PDF
Report
Presentation
Webcast
Regulatory
2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level
PDF
Report
Presentation
Webcast
Regulatory
2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch
PDF
Report
Presentation
Webcast
Regulatory
2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study
PDF
Report
Presentation
Webcast

Posts navigation

Older posts
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Contact

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q4 2020 (October – December 2020), which is now available on the company’s website: https://www.ascelia.com/ir-media/reports-presentations/SIGNIFICANT EVENTS IN Q4 2020 Upgraded estimate of the addressable market for Mangoral to $500-600 million annually (p ...
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start (en)

About us

  • Start (en)
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings
  • IMPORTANT INFORMATION

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all